ViPS Biomedical Services, fabricante de software BI para el sector de la sanidad con oficinas centrales en Baltimore, Washington, presentará en la conferencia anual de la DIA (Asociación de información sobre fármacos) su tecnología para la captura electrónica de datos, esencial para optimizar recursos frente al manejo de papel. El software que desarrolla ViPS está enfocado a empresas que se dedican a la investigación y desarrollo, en particular de biotecnología, farmacéuticas y de suministros para los servicios médicos.
NOTA DE PRENSA EN INGLÉS
BALTIMORE, March 22 — ViPS, Inc., a leader in business intelligence solutions for healthcare and major provider of clinical trial services that increase efficiencies for life sciences, today announced that it will present at the 19th Annual DIA Clinical Data Management Symposium at the Philadelphia Downtown Marriott from March 21 through March 24.
This year’s Drug Information Association (DIA) conference will focus on the people, processes and technologies that constitute the core functions of clinical data management in today’s global business environment.
Anne Zielinski, Vice President of ViPS’ life science business group, ViPS BioMedical Services, will present at the March 24th session: Electronic Data Capture 2: Going into Production. Ms. Zielinski, speaking on the full ROI and benefit of electronic data capture (EDC) technology in complex trials, will provide real-world case studies on how EDC can have a positive impact on data quality and efficiencies when compared to paper.
«ViPS BioMedical Services is a premier provider in delivering EDC technology and services to the life science industries,» notes Zielinski. «For more than 10 years, our targeted solutions have helped pharmaceutical, biotechnology, medical device and contract research organizations adopt more efficient development processes. Our commitment to EDC will go beyond automating paper processes, bringing the full benefit of technological advances to clinical trials.»
Pinche aquí para visitar nuestro FORO y comentar esta información.